MAGEB16 as an epigenetic timing regulator linking X-chromosome biology to neurodevelopmental vulnerability in Autism Spectrum Disorder

Abstract

MAGEB16 (Melanoma-associated antigen B16) is an X-linked cancer-testis antigen belonging to the MAGE-B family, whose expression is tightly regulated by a promoter DNA-methylation switch that restricts transcription primarily to the male germ line under normal physiological conditions. In addition to its established roles in spermatogenesis and oncogenesis, emerging functional, epigenomic, and genetic evidence points to MAGEB16 as an epigenetically sensitive modifier of early developmental programs implicated in neurodevelopmental disorders such as Autism Spectrum Disorder (ASD). In this study, we performed an integrative analysis combining MAGEB16’s chromosomal context, molecular interaction networks, and methylation-dependent regulatory features, alongside experimental depletion datasets from pluripotent stem cells, perinatal cord-blood methylome data from ASD cohorts, peripheral transcriptomics linked to neuropsychiatric risk and recently reported genetic variant associations. Our synthesis identifies underlying evidence indicating that MAGEB16 participates in epigenetically regulated lineage specification processes during early embryonic development. We propose a unified model in which MAGEB16 acts as a dosage- and timing-dependent regulator of early lineage commitment. Disruption of its epigenetic control, particularly during X-chromosome-enriched developmental periods, may influence neurodevelopmental pathways toward ASD-associated phenotypes. These findings position MAGEB16 as a candidate epigenetic-susceptibility factor linking germline-restricted regulatory changes, that could influence early brain development and increase the risk for neurodevelopmental conditions.